{
  "uc16_analysis_results": {
    "case_summary": {
      "case_id": "UC16-2025-001",
      "analysis_date": "2025-01-20",
      "patient_id": "PAT-2025-001",
      "primary_diagnosis": "Metastatic Pancreatic Adenocarcinoma",
      "stage": "T3N1M1 (Stage IV)",
      "confidence_score": 0.92
    },
    "agent_contributions": {
      "radiology_agent": {
        "confidence": 0.94,
        "processing_time_seconds": 45.2,
        "key_findings": [
          "Primary pancreatic head mass (3.4 x 3.0 cm)",
          "Multiple hepatic metastases (largest 2.3 cm)",
          "Superior mesenteric vein involvement",
          "Biliary ductal dilatation"
        ],
        "staging_contribution": {
          "t_stage": "T3",
          "n_stage": "N1",
          "m_stage": "M1",
          "resectability": "Unresectable"
        },
        "ai_insights": {
          "tumor_volume": "15.2 cmÂ³",
          "heterogeneity_index": 0.78,
          "vascular_involvement_probability": 0.91,
          "metastases_count": 8
        }
      },
      "pathology_agent": {
        "confidence": 0.89,
        "processing_time_seconds": 32.1,
        "key_findings": [
          "Moderately differentiated adenocarcinoma",
          "Grade 2 tumor",
          "CK7+/CK20- immunoprofile",
          "Lymphovascular invasion present"
        ],
        "histological_type": "Ductal adenocarcinoma",
        "grade": "Grade 2 (Moderately differentiated)",
        "immunohistochemistry_panel": {
          "ck7": "Positive (Strong)",
          "ck20": "Negative",
          "ttf1": "Negative",
          "ca19_9": "Positive (Moderate)"
        },
        "molecular_markers": [
          "Ki-67: 65% (High proliferation)",
          "p53: Mutant pattern",
          "SMAD4: Loss of expression"
        ]
      },
      "genomics_agent": {
        "confidence": 0.96,
        "processing_time_seconds": 67.8,
        "key_findings": [
          "KRAS G12D mutation (42% VAF)",
          "TP53 R273H mutation (38% VAF)",
          "CDKN2A loss (nonsense mutation)",
          "SMAD4 loss (nonsense mutation)"
        ],
        "mutation_signature": "Classic pancreatic cancer profile",
        "therapeutic_targets": [
          {
            "target": "KRAS G12D",
            "drugs": ["Investigational KRAS inhibitors"],
            "evidence_level": "Preclinical"
          },
          {
            "target": "Homologous recombination pathway",
            "drugs": ["PARP inhibitors"],
            "evidence_level": "Limited"
          }
        ],
        "biomarkers": {
          "msi_status": "MSS",
          "tmb": "Low (3.2 mut/Mb)",
          "hrd_score": "Negative (15)",
          "pd_l1": "Low (5%)"
        },
        "pharmacogenomics": [
          "UGT1A1*28/*28: Irinotecan dose reduction needed",
          "TPMT normal: Standard dosing for 6-MP/azathioprine"
        ]
      },
      "patient_history_agent": {
        "confidence": 0.87,
        "processing_time_seconds": 28.5,
        "key_findings": [
          "3-month symptom progression",
          "Strong family history of cancer",
          "Diabetes comorbidity",
          "Former smoking history"
        ],
        "timeline_analysis": {
          "symptom_onset": "October 2024",
          "diagnosis_delay": "3 months",
          "progression_rate": "Rapid",
          "performance_decline": "Moderate"
        },
        "risk_factors": [
          {
            "factor": "Family history",
            "impact": "High",
            "details": "Sister with BRCA1, mother with breast cancer"
          },
          {
            "factor": "Smoking history",
            "impact": "Moderate",
            "details": "15 pack-years, quit 2019"
          },
          {
            "factor": "Diabetes",
            "impact": "Moderate",
            "details": "Type 2, diagnosed 2022"
          }
        ],
        "comorbidity_impact": {
          "diabetes": "May affect treatment tolerance",
          "hypertension": "Well controlled, minimal impact"
        }
      },
      "clinical_research_agent": {
        "confidence": 0.91,
        "processing_time_seconds": 52.3,
        "key_findings": [
          "Strong evidence for combination chemotherapy",
          "FOLFIRINOX preferred for fit patients",
          "Limited targeted therapy options",
          "Poor prognosis markers present"
        ],
        "treatment_recommendations": [
          {
            "line": "First-line",
            "regimen": "FOLFIRINOX",
            "evidence_level": "1A",
            "expected_response_rate": "31.6%",
            "median_os": "11.1 months",
            "considerations": "Good performance status required"
          },
          {
            "line": "Alternative first-line",
            "regimen": "Gemcitabine + nab-paclitaxel",
            "evidence_level": "1A",
            "expected_response_rate": "23%",
            "median_os": "8.5 months",
            "considerations": "Better tolerance profile"
          },
          {
            "line": "Second-line",
            "regimen": "5-FU + liposomal irinotecan",
            "evidence_level": "1B",
            "expected_response_rate": "16%",
            "median_os": "6.2 months",
            "considerations": "After gemcitabine failure"
          }
        ],
        "prognostic_factors": [
          {
            "factor": "CA 19-9 level (189 U/mL)",
            "impact": "Negative",
            "hazard_ratio": 1.8
          },
          {
            "factor": "Multiple metastatic sites",
            "impact": "Negative",
            "hazard_ratio": 1.6
          },
          {
            "factor": "ECOG PS 1",
            "impact": "Acceptable",
            "hazard_ratio": 1.0
          }
        ]
      },
      "clinical_trials_agent": {
        "confidence": 0.84,
        "processing_time_seconds": 41.7,
        "key_findings": [
          "Limited targeted therapy trials available",
          "Precision medicine trials appropriate",
          "Immunotherapy combinations under investigation",
          "Geographic access considerations"
        ],
        "trial_matches": [
          {
            "trial_id": "NCT03768414",
            "title": "Pancreatic Cancer Precision Medicine Trial",
            "match_score": 0.89,
            "phase": "Phase II",
            "status": "Recruiting",
            "primary_endpoint": "Progression-free survival",
            "eligibility": "Excellent match",
            "location_access": "Johns Hopkins (150 miles)"
          },
          {
            "trial_id": "NCT04390763",
            "title": "Immunotherapy Combination Trial",
            "match_score": 0.72,
            "phase": "Phase I/II",
            "status": "Active, not recruiting",
            "primary_endpoint": "Safety and tolerability",
            "eligibility": "Good match",
            "location_access": "UC San Francisco (300 miles)"
          }
        ],
        "recommendations": [
          "Consider precision medicine trial enrollment",
          "Standard of care remains appropriate",
          "Monitor for new KRAS-targeted trials",
          "Consider referral to academic center"
        ]
      }
    },
    "integrated_assessment": {
      "diagnostic_certainty": 0.92,
      "staging_accuracy": 0.94,
      "treatment_complexity": "High",
      "prognosis": {
        "category": "Poor",
        "estimated_survival_months": "8-12",
        "confidence": 0.88,
        "factors": [
          "Metastatic disease",
          "Multiple poor prognostic markers",
          "Limited targeted options"
        ]
      },
      "multidisciplinary_recommendations": [
        {
          "specialty": "Medical Oncology",
          "action": "Initiate systemic chemotherapy",
          "urgency": "Within 1-2 weeks",
          "details": "FOLFIRINOX vs Gem/nab-paclitaxel based on PS"
        },
        {
          "specialty": "Interventional Radiology",
          "action": "Consider biliary stenting",
          "urgency": "If symptomatic obstruction",
          "details": "Monitor bilirubin levels"
        },
        {
          "specialty": "Palliative Care",
          "action": "Early integration",
          "urgency": "Within 2-4 weeks",
          "details": "Symptom management and goals of care"
        },
        {
          "specialty": "Genetic Counseling",
          "action": "Family history evaluation",
          "urgency": "Non-urgent",
          "details": "BRCA testing given family history"
        }
      ]
    },
    "quality_metrics": {
      "total_processing_time_seconds": 267.6,
      "agent_consensus_score": 0.89,
      "data_completeness": 0.93,
      "confidence_distribution": {
        "high_confidence": 5,
        "moderate_confidence": 1,
        "low_confidence": 0
      },
      "evidence_quality": "High",
      "recommendation_strength": "Strong"
    }
  }
}
